8F8 Stock Chart & Stats
€2.08
€0.06(6.50%)
At close: 4:00 PM EST
€2.08
€0.06(6.50%)
Day’s Range― - ―
52-Week Range€0.97 - €2.32
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€92.10M
Enterprise Value€1.17K
Total Cash (Recent Filing)€14.23M
Total Debt (Recent Filing)€929.00K
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding53,330,242
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageThe very low debt burden reduces interest and refinancing pressure while preserving financial flexibility relative to a highly leveraged biotech. A sizable equity base provides a stronger starting position for funding development activities, although ongoing losses still require careful capital management.
Differentiated Lead CandidateResomelagon addresses a clinically relevant objective by seeking inflammation resolution without broad immune suppression. If clinical development validates this profile, the approach could support differentiation in autoimmune and inflammatory markets and create partnering or commercialization opportunities.
Partnership-based Value CreationA licensing or co-development model could provide non-linear value creation if resomelagon advances, allowing SynAct to monetize development progress without independently funding every later-stage activity. Such arrangements could also bring commercial capabilities and reduce execution demands on the small organization.
Bears Say
No Commercial RevenueWithout recurring product revenue, SynAct lacks an operating cash engine to fund research and clinical trials. Its financial outlook therefore depends heavily on successful development milestones, future partnering, or additional capital rather than on established customer demand and repeat sales.
Sustained Cash BurnPersistent negative operating and free cash flow means the company consumes capital while its pipeline remains in development. Continued burn can restrict strategic flexibility and increase dependence on equity financing or other external funding, creating dilution and execution risk over the coming quarters.
Heavy And Uneven LossesLarge, volatile losses show that profitability is not yet supported by a commercial revenue base. The deterioration after 2024–2025 suggests cost control and earnings progress remain uneven, leaving future financial performance dependent on containing spending and advancing the pipeline toward monetization.
SynAct Pharma AB News
8F8 FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was €0.97 and its highest was €2.32 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is €92.10M.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Nov 03, 2026 which is in 54 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on Aug 20, 2026. The company reported -€0.035 earnings per share for the quarter.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 53,330,242 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -€0.035 in its last earnings report. Following the earnings report the stock price went down -11.574%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in DE:8F8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
InDex Pharmaceuticals Holding AB
―
Active Biotech AB
―
Cantargia AB
―